Progress of KRAS G12C mutations in non-small cell lung cancer / 国际肿瘤学杂志

ABSTRACT

With the continuous in-depth research on the mechanism of KRAS G12C mutations in targeted therapy of non-small cell lung cancer, KRAS G12C has evolved from non producible to an important targeted therapy site. The KRAS G12C mutation inhibitor has achieved dual progress in efficiency and survival in targeted therapy of non-small cell lung cancer. Although drug resistance is inevitable with treatment, research on drug resistance mechanisms has found that combination medication is one of the ways to overcome or reduce drug resistance.